Bioventus Agrees to Nationwide Contract with Aetna™ Medicare Advantage Plans for DUROLANE® for Knee Osteoarthritis

Rhea-AI Summary

Bioventus Inc. (BVS) has secured a nationwide contract with Aetna™ Medicare Advantage plans, granting over 3 million members access to DUROLANE, a single-injection hyaluronic acid-based joint-fluid treatment for knee osteoarthritis (OA) pain, starting January 1, 2024.

DURHAM, N.C., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has agreed to a nationwide contract with Aetna™ Medicare Advantage plans. Beginning January 1, 2024, over 3 million Aetna™ Medicare Advantage plan members will have access to DUROLANE to treat knee osteoarthritis (OA) pain. DUROLANE, is a single-injection hyaluronic acid (HA)-based joint-fluid treatment for patients. DUROLANE will be one of two single-injection HA products under contract.

OA involves the breakdown, or degeneration, of cartilage and the synovial fluid that cushions and lubricates joint tissues. Injection treatments of HA-based products, such as DUROLANE, help manage knee OA pain.

“We are pleased DUROLANE is among the preferred options available to both Aetna™ Medicare Advantage members and physicians,” said Anthony Doyle, General Manager, Pain Treatments and Restorative Therapies for Bioventus. “Both now have access to a safe HA product that is proven to provide relief from knee OA pain.”

About Bioventus

Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations for Active Healing from Bioventus include offerings for Pain Treatments, Restorative Therapies and Surgical Solutions. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.bioventus.com, and follow the Company on LinkedIn and Twitter. Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.

Investor and Media Inquiries:
Dave Crawford
919-474-6787
dave.crawford@bioventus.com

FAQ

What is the latest contract secured by Bioventus Inc. (BVS)?

Bioventus Inc. (BVS) has secured a nationwide contract with Aetna™ Medicare Advantage plans, granting over 3 million members access to DUROLANE, a single-injection hyaluronic acid-based joint-fluid treatment for knee osteoarthritis (OA) pain, starting January 1, 2024.

What is DUROLANE and how does it help with knee osteoarthritis (OA) pain?

DUROLANE is a single-injection hyaluronic acid (HA)-based joint-fluid treatment for patients suffering from knee osteoarthritis (OA) pain. It helps manage knee OA pain by providing relief through injection treatments of HA-based products.

Who is the General Manager of Pain Treatments and Restorative Therapies for Bioventus Inc. (BVS)?

Anthony Doyle is the General Manager of Pain Treatments and Restorative Therapies for Bioventus Inc. (BVS).

What is the significance of the contract with Aetna™ Medicare Advantage plans for Bioventus Inc. (BVS)?

The contract with Aetna™ Medicare Advantage plans is significant as it provides access to over 3 million members, offering DUROLANE as a preferred option for knee OA pain relief, which is a positive development for Bioventus Inc. (BVS).